MedTrace Logo

Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)

NCT00476034 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1312

Last updated 2012-05-21

No results posted yet for this study

Summary

This 39-week, active controlled, study is designed to assess long-term efficacy, safety and tolerability of lumiracoxib 100mg od in patients with osteoarthritis (OA) of the knee who participated in the 13-week core CCOX189A2361 study.

Conditions

Interventions

DRUG

lumiracoxib

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2004-11-30

Countries

  • Australia
  • Austria
  • Czechia
  • Finland
  • Germany
  • Hungary
  • Israel
  • Netherlands
  • New Zealand
  • Poland
  • Slovakia
  • South Africa
  • Spain
  • Sweden
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00476034 on ClinicalTrials.gov